Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation of protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. T...
Saved in:
| Main Author: | Mohammed Hawash |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/19/1656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01) -
Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
by: Jonatan Kaszubski, et al.
Published: (2024-11-01) -
High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01) -
EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)